| answer text |
<p>As we move into the second phase of negotiations we are confident of agreeing a
bold and ambitious economic partnership with the EU that is of greater scope than
any such existing agreement.</p><p><strong> </strong></p><p>The role of preferential
or non-preferential Rules of Origin in any deal, and our approach to minimising administration
and friction, will depend on the precise nature of the agreement between the UK and
the EU.</p><p><strong> </strong></p><p>We have been working closely with the Department
of Health and Social Care and the Office for Life Sciences to understand the needs
of the pharmaceutical industry. Our Ministers also have regular engagement with a
variety of Life Sciences companies and trade bodies, including the Association of
British Pharmaceutical Industry and the BioIndustry Association through the cross-government
Life Sciences Steering Group.</p><p> </p>
|
 |
